Incyte Corporation (INCY:NASDAQ) closed at $120.97 on November 13, 2026, down 0.60% on the day. The stock trades 8.8% below its 52-week high of $132.60 and 35.5% above its 52-week low of $89.25. Over the past year, it gained 16.1%. Incyte Corporation is part of the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch).
In 252 trading sessions since November 13, 2025, INCY closed higher on 123 days (49%). Its best day was July 28, 2026 (+9.30%) and its worst was February 10, 2026 (-8.24%). It never moved 10% or more in a single session.
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The company's clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the company's clinical stage products include epacadostat, w...
Find more stocks like INCY with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.